1. Immunoglobulin free light chains: an inflammatory biomarker of diabetes.
- Author
-
Matsumori A, Shimada T, Shimada M, and Drayson MT
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Diabetes Mellitus, Type 2 diagnosis, Female, Humans, Male, Middle Aged, NF-kappa B physiology, Diabetes Mellitus, Type 2 immunology, Immunoglobulin Light Chains blood, Inflammation diagnosis
- Abstract
Objective: Inflammation is increasingly understood as playing an important role in type 2 diabetes mellitus (T2D) development. A critical mechanism of the inflammatory cascade in developing T2D is nuclear factor-kappa B (NF-kB) activation. As immunoglobulin free light chains (FLC) could be a biomarker of activation of NF-kB, we measured FLC in patients with T2D., Subjects: The age range of the 77 patients with T2D and the 75 healthy control participants were 45-87 years (median 60) and 25-72 years (median 51), respectively., Methods: Serum FLC kappa and lambda were assayed by a competitive-inhibition multiplex Luminex assay., Results: The concentration of circulating FLC the kappa/lambda ratio was lower in patients with T2D than in healthy volunteers. The area under the receiver operating curve (ROC-AUC) of the FLC kappa/lambda ratio showed the largest ROC-AUC compared with other FLC variables and hemoglobin A1c (HbA1c). The diagnostic performance for distinguishing between T2D and healthy control was a sensitivity of 0.96 and a specificity of 1. The odds ratio was 0.000018., Conclusions: These results suggest that FLC kappa/lambda may be more specific and sensitive for the diagnosis of T2D than HbA1c, and thus represents a potentially promising biomarker of inflammation.
- Published
- 2020
- Full Text
- View/download PDF